Figure 1 | Scientific Reports

Figure 1

From: Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs

Figure 1The alternative text for this image may have been generated using AI.

Prognosis of HR+ breast cancer patients after low-dose CY + ET treatment. (A) Disease control in patients after low-dose CY + ET treatment. (B) PFS of patients after low-dose CY + ET treatment. (C) Patients with reduced peripheral blood Treg cell counts after low-dose CY + ET treatment have a better prognosis. (D) Patients with increased CD8+CD28+ T-cell counts in peripheral blood after low-dose CY + ET treatment had a better prognosis.

Back to article page